A Phase 2 interventional study of PF-07220060 and letrozole in Breast Cancer, sponsored by Pfizer. Completed at 51 sites in 13 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-15.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing atirmociclib in Breast Neoplasms — 4 open to participants now, 8 under way, 2 of them phase 3. atirmociclib · Breast Neoplasms.
Among the 10 studies testing atirmociclib in Breast Neoplasms, this one is the 7th largest by enrollment, is one of 3 that started in 2024, is one of 4 in phase 2, and was the 6th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →4 of the 10 studies testing atirmociclib in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, United Kingdom
Ages 18+ · Women only
Pfizer · Sites in United States, Argentina, China and 5 more countries
Ages 18+
Hoffmann-La Roche · Sites in United States, Australia, France and 6 more countries
Ages 18+
Pfizer
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 2
First in 2018; this study’s year is marked. 3 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 121 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 262 across the 10 interventional studies. Of the 2 that completed or were terminated, 1 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 10 have an industry lead sponsor. The 4 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
182 studies in Breast Neoplasms by Pfizer: 6 open now, 26 under way, 7 of them phase 3. Of 145 finished, 94 (65%) have results posted.
Among the 182 studies in Breast Neoplasms by Pfizer, this one is the 46th largest by enrollment of the 121 interventional ones that give a count, is one of 11 that started in 2024, is one of 43 in phase 2, and was the 168th registered.
Pfizer’s Breast Neoplasms studies by the year they started, since 1998.
None of the studies under way reaches primary completion within a year.
Among the 10 studies testing atirmociclib in Breast Neoplasms, from their registry updates:
Among Pfizer’s 182 in Breast Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to learn about the effects of the study medicine PF-07220060 plus letrozole, compared with the effects of taking letrozole alone without PF-07220060 for treatment of breast cancer.
This study is seeking for participants who are:
Participants will be randomly assigned (like flipping a coin) to receive the treatment (PF-07220060 plus letrozole) or letrozole alone. Both PF-07220060 and letrozole are taken by mouth. PF-07220060 will be taken twice a day for 14 days. Letrozole will be taken once a day for 14 days.
Participants will have a screening period for up to 28 days. If deemed fit, they will receive study treatment for 14 days, and then will have a follow-up visit about 28 days after their last dose.
All participants will have at least one biopsy during the study. Biopsy is the removal of cells or tissues for examining. All participants will have a biopsy on Day 14.
Additional assessments for safety including blood draws and interviews done by the site staff will be completed during the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PF-07220060 given as tablet by mouth twice a day for 14 days. Letrozole given as tablet by mouth once a day for 14 days.
Drug: PF-07220060 · Drug: letrozole
Letrozole given by mouth once a day for 14 days.
Drug: letrozole
PF-07220060 given as tablet by mouth twice a day for 14 days.
Letrozole given as tablet by mouth once a day for 14 days
Also known as: Femara
Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14
CCCA was determined by antigen Kiel 67 (Ki-67) value as decided by Sponsor. Ki-67 was extensively used as a prognostic and predictive biomarker for cancer diagnosis and treatment. Ki-67 expression was measured by immunohistochemistry. Assessment at Day 14 was done in blinded manner by centrally assessed biopsy.
Time frame: Day 14
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity and was congenital anomaly/birth defect. AEs that occurred on or after the first dose of study treatment and before the end of treatment (35 days after last dose of study treatment or start of subsequent anti-cancer therapy minus 1 day, whichever occurred first) was considered TEAEs. All AEs (SAEs and all other AEs) were considered for evaluation.
Time frame: From start of study intervention (Day 1) up to 35 days after the last dose of study intervention or start of subsequent anti-cancer therapy minus 1 day, whichever occurred first (approximately up to 49 days)
Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs)
An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity and was congenital anomaly/birth defect. AEs that occurred on or after the first dose of study treatment and before the end of treatment (35 days after last dose of study treatment or start of subsequent anti-cancer therapy minus 1 day, whichever occurred first) was considered TEAEs.
Time frame: From start of study intervention (Day 1) up to 35 days after the last dose of study intervention or start of subsequent anti-cancer therapy minus 1 day, whichever occurred first (approximately up to 49 days)
Number of Participant With AEs Leading to Any Study Intervention Discontinuation
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
Time frame: During study treatment (maximum up to 14 days)
Circulating Tumor Deoxyribonucleic Acid (ctDNA) Methylation Tumor Fraction Values at Baseline and Day 14
The methylation-based tumor fraction of a single sample was estimated from methylation signals across targeted regions from the methylation panel, was calibrated using training data including cancer free donors and participants with mixed cancer types. The method included a data-informed differentially methylated region selection targeting regions with high pan cancer signal to noise ratio. This value was an estimate of the proportion of the sample that was tumor derived and expressed as percentage of DNA. ctDNA methylation tumor fraction values were reported in percentage at Baseline and Day 14 were assessed from central laboratory.
Time frame: Baseline (the last measurement on or prior to date of the first dose of study intervention if the first dose is not missing, otherwise, on or prior to the randomization date), Day 14 (pre-dose)
Plasma Concentration (Ctrough) of PF-07220060 on Day 14
Ctrough was pre-dose plasma concentration.
Time frame: Pre-dose (within 30 minutes before dosing) on Day 14
Plasma Concentration at the Time of Biopsy (Cperi-biopsy) of PF-07220060 on Day 14
Cperi-biopsy was plasma concentration at the time of biopsy.
Time frame: Within 1 hour before or 1 hour after biopsy on Day 14
Change From Baseline in Antigen Ki-67 at Day 14
Ki-67 was extensively used as a prognostic and predictive biomarker for cancer diagnosis and treatment. Ki-67 expression was measured by immunohistochemistry and expressed as percentage of cells. Assessment at baseline and Day 14 was done in blinded manner by centrally assessed biopsy.
Time frame: Baseline (the last measurement on or prior to date of the first dose of study intervention if the first dose was not missing, otherwise, on or prior to the randomization date), Day 14 (pre-dose)
Relative Reduction (%) of Ki-67 From Baseline at Day 14
Ki-67 was extensively used as a prognostic and predictive biomarker for cancer diagnosis and treatment. Ki-67 expression was measured by immunohistochemistry. Assessment at baseline and Day 14 was done in blinded manner by centrally assessed biopsy. Relative reduction at Day 14 was calculated as:100 \*(1-Ki-67 at Day 14/Ki-67 at Baseline). Relative reduction was expressed in percentage reduction.
Time frame: Baseline (the last measurement on or prior to date of the first dose of study intervention if the first dose was not missing, otherwise, on or prior to the randomization date), Day 14 (pre-dose)
| Milestone | PF-07220060 + Letrozole | Letrozole Alone |
|---|---|---|
| Started | 59 | 62 |
| Completed | 59 | 61 |
| Not completed | 0 | 1 |
| Withdrew: Other | 0 | 1 |
| Milestone | PF-07220060 + Letrozole | Letrozole Alone |
|---|---|---|
| Started | 59 | 62 |
| Completed | 59 | 62 |
| Not completed | 0 | 0 |
CCCA was determined by antigen Kiel 67 (Ki-67) value as decided by Sponsor. Ki-67 was extensively used as a prognostic and predictive biomarker for cancer diagnosis and treatment. Ki-67 expression was measured by immunohistochemistry. Assessment at Day 14 was done in blinded manner by centrally assessed biopsy.
| Percentage of participants | PF-07220060 + Letrozole | Letrozole Alone |
|---|---|---|
| Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14 | 88.2 (76.6 to 94.5) | 17.9 (10.0 to 29.8) |
An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An serious adverse event (SAE) was defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity and was congenital anomaly/birth defect. AEs that occurred on or after the first dose of study treatment and before the end of treatment (35 days after last dose of study treatment or start of subsequent anti-cancer therapy minus 1 day, whichever occurred first) was considered TEAEs. All AEs (SAEs and all other AEs) were considered for evaluation.
| Participants | PF-07220060 + Letrozole | Letrozole Alone |
|---|---|---|
| Number of Participants With Treatment Emergent Adverse Events (TEAEs) | 29 | 24 |
An SAE was defined as any untoward medical occurrence that, at any dose, met one or more of the criteria: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity and was congenital anomaly/birth defect. AEs that occurred on or after the first dose of study treatment and before the end of treatment (35 days after last dose of study treatment or start of subsequent anti-cancer therapy minus 1 day, whichever occurred first) was considered TEAEs.
| Participants | PF-07220060 + Letrozole | Letrozole Alone |
|---|---|---|
| Number of Participants With Treatment Emergent Serious Adverse Events (TESAEs) | 1 | 0 |
An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.
| Participants | PF-07220060 + Letrozole | Letrozole Alone |
|---|---|---|
| Number of Participant With AEs Leading to Any Study Intervention Discontinuation | 0 | 0 |
The methylation-based tumor fraction of a single sample was estimated from methylation signals across targeted regions from the methylation panel, was calibrated using training data including cancer free donors and participants with mixed cancer types. The method included a data-informed differentially methylated region selection targeting regions with high pan cancer signal to noise ratio. This value was an estimate of the proportion of the sample that was tumor derived and expressed as percentage of DNA. ctDNA methylation tumor fraction values were reported in percentage at Baseline and Day 14 were assessed from central laboratory.
| Percentage of DNA | PF-07220060 + Letrozole | Letrozole Alone |
|---|---|---|
| Baseline | 0.065 (0.007 to 5.171) | 0.047 (0.003 to 0.418) |
| Day 14 | 0.049 (0.008 to 0.397) | 0.036 (0.006 to 0.219) |
Ctrough was pre-dose plasma concentration.
| Nanogram per milliliter | PF-07220060 + Letrozole |
|---|---|
| Plasma Concentration (Ctrough) of PF-07220060 on Day 14 | 669.5 ± 39 |
Cperi-biopsy was plasma concentration at the time of biopsy.
| Nanogram per milliliter | PF-07220060 + Letrozole |
|---|---|
| Plasma Concentration at the Time of Biopsy (Cperi-biopsy) of PF-07220060 on Day 14 | 808.2 ± 54 |
Ki-67 was extensively used as a prognostic and predictive biomarker for cancer diagnosis and treatment. Ki-67 expression was measured by immunohistochemistry and expressed as percentage of cells. Assessment at baseline and Day 14 was done in blinded manner by centrally assessed biopsy.
| Percentage of cells | PF-07220060 + Letrozole | Letrozole Alone |
|---|---|---|
| Change From Baseline in Antigen Ki-67 at Day 14 | -30.120 (-96.79 to 14.66) | -17.270 (-56.65 to 14.10) |
Ki-67 was extensively used as a prognostic and predictive biomarker for cancer diagnosis and treatment. Ki-67 expression was measured by immunohistochemistry. Assessment at baseline and Day 14 was done in blinded manner by centrally assessed biopsy. Relative reduction at Day 14 was calculated as:100 \*(1-Ki-67 at Day 14/Ki-67 at Baseline). Relative reduction was expressed in percentage reduction.
| Percentage reduction | PF-07220060 + Letrozole | Letrozole Alone |
|---|---|---|
| Relative Reduction (%) of Ki-67 From Baseline at Day 14 | 97.277 (-33.98 to 99.80) | 72.414 (-139.88 to 98.28) |
Collected over From start of study intervention (Day 1) up to 35 days after the last dose of study intervention or start of subsequent anti-cancer therapy minus 1 day, whichever occurred first (approximately up to 49 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-07220060 + Letrozole | 0/59 (0%) | 1/59 (1.7%) | 21/59 (35.6%) |
| Letrozole Alone | 0/62 (0%) | 0/62 (0%) | 16/62 (25.8%) |
| Event | PF-07220060 + Letrozole | Letrozole Alone |
|---|---|---|
| Post procedural haematomaInjury, poisoning and procedural complications | 1/59 | 0/62 |
| Event | PF-07220060 + Letrozole | Letrozole Alone |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 11/59 | 1/62 |
| NauseaGastrointestinal disorders | 8/59 | 3/62 |
| HeadacheNervous system disorders | 2/59 | 7/62 |
| AstheniaGeneral disorders | 6/59 | 3/62 |
| Hot flushVascular disorders | 2/59 | 6/62 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/59 | 4/62 |
| FatigueGeneral disorders | 3/59 | 3/62 |
| Age, Continuous(Years) | PF-07220060 + Letrozole | Letrozole Alone | Total |
|---|---|---|---|
| Mean | 66.5 ± 7.1 | 64.2 ± 7.4 | 65.3 ± 7.3 |
| Sex: Female, Male(Participants) | PF-07220060 + Letrozole | Letrozole Alone | Total |
|---|---|---|---|
| Female | 59 | 62 | 121 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | PF-07220060 + Letrozole | Letrozole Alone | Total |
|---|---|---|---|
| Hispanic or Latino | 12 | 8 | 20 |
| Not Hispanic or Latino | 39 | 39 | 78 |
| Unknown or Not Reported | 8 | 15 | 23 |
| Race (NIH/OMB)(Participants) | PF-07220060 + Letrozole | Letrozole Alone | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 |
| Asian | 2 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 2 | 2 |
| White | 49 | 41 | 90 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 7 | 16 | 23 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jul 2024 to primary completion in Jul 2025, 11 months.
Results were first posted in Jul 2026, 1 year after primary completion.
Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 11 months is below that.
Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Atirmociclib